Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018

SELL
$1.45 - $6.15 $125,259 - $531,273
-86,386 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$1.65 - $2.5 $559,477 - $847,692
-339,077 Reduced 79.7%
86,386 $143,000
Q1 2018

May 15, 2018

BUY
$1.25 - $2.65 $531,828 - $1.13 Million
425,463 New
425,463 $787,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Sabby Management, LLC Portfolio

Follow Sabby Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sabby Management, LLC with notifications on news.